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The androgen receptor (AR) is an important target in castration-
resistant prostate cancer (CRPC) as the progression of the disease is
still largely dependent on androgen signalling. The recommenda-
tion to continue with androgen deprivation therapy is reasonable,
as cessation and restoration of testosterone levels may have an
adverse impact on survival. Antiandrogen withdrawal may also be
attempted in all patients, as some patients are long-term re-
sponders. In one study, 19% of patients showed no signs of pro-
gression 1 year after antiandrogen withdrawal.1 Bissada et al.
reported on a case in which the duration of response was for more
than 3 years after antiandrogen withdrawal.2
First-generation antiandrogens such as ﬂutamide, bicalutamide,
and nilutamide have shown to be effective against prostate cancer
relapse after failure of ﬁrst-line androgen deprivation therapy
(ADT). Studies have indicated PSA responses of 14e48% with
bicalutamide and up to 50% with nilutamide.3e9 Among patients
with minimal or no bone scan involvement and low baseline
prostate-speciﬁc antigen (PSA) who were started on high-dose
ketoconazole, PSA levels decreased by at least 75%.10 But high
doses of ketoconazole have been linked to clinically signiﬁcant
toxicity. Therefore, as shown in a small, retrospective study, low-
dose ketoconazole may be an option for patients with biochem-
ical failure who have failed ADT.11 With second-line hormonal
manipulation using ketoconazole, response rates of between 11%
and 13% were reported. There was also a marked palliation of pain
in a subset of patients. Low-dose ketoconazole appears to be well* Corresponding author: Paul Mainwaring (pmainwaring@iconcancercare.com.au).
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p2287-8882 e2287-903Xtolerated, is relatively low cost, and easy to administer. For second-
line hormonal manipulation with prednisone, approximately 1 in 3
patients had a PSA decrease of > 50%. Theremay be a dose-response
relationship between glucocorticoid dose and PSA decline. Recent
data has highlighted a signiﬁcant beneﬁt of dexamethasone over
prednisone in the palliative setting.12
According to international guidelines, second-line hormonal
manipulation continued to elicit a biochemical response in CRPC
patients without signs of distant metastases.13e15
PSA responses of 14e75% have been reported with these agents,
but duration of response was generally less than 6 months, without
evidence of survival beneﬁt. Another limitation of this manipulation
is its side effect proﬁle. Nevertheless, second-line hormonal therapy
continues to be a viable option in limited resource environments.
According to the 2015 St Gallen Advances Prostate Cancer
Consensus, novel agents such as abiraterone and enzalutamidemay
be approved but will be unavailable for many patients, especially in
the Asia Paciﬁc region, due to cost.162. The importance of early initiation of novel agents instead
of vintage second-line hormonal manipulation
In recent large, phase III international trials, clear survival beneﬁt
has been observed with the use of these novel agents in patients
with metastatic castration-resistant prostate cancer (mCRPC) who
failed ﬁrst-line ADT. Before the emergence of the next generation
agents these patients were treated with vintage secondary hor-
mones, which includemainly ﬁrst-generation antiandrogens such as
bicalutamide and ﬂutamide, and old secondary hormonal agents
such as oestrogens, ketoconazole and corticosteroids.
In the COU-302 clinical trial, the use of abiraterone plus predni-
sone in chemo-naïve patients who have failed ﬁrst-line ADT had
signiﬁcantly longer overall survival (OS) than patients who had
prednisone alone.17 Abiraterone's treatment effect was more pro-
nounced when adjusting for prednisone patients who received
subsequent abiraterone. Abiraterone also doubled the time to
radiographic progression-free survival (rPFS) and there was
improvement in all clinical end points including time to opiate use.18
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progression on ADT signiﬁcantly prolonged OS and rPFS. Enzalu-
tamide also delayed median time to chemotherapy by 17 months.19
Compared to second-line hormonal manipulation, the early use of
novel agents provides signiﬁcant survival and clinical beneﬁts
whilst maintaining quality of life.
Addressing a clinically relevant question, the addition of enza-
lutamide compared to bicalutamide when patients are progressing
on luteinising hormone-releasing hormone (LHRH) therapy alone
was recently demonstrated to prolong PFS, time to PSA progression,
and time on treatment (TERRAIN trial).20 Adverse events observed
were consistent with the known safety proﬁle of enzalutamide.
Practice should be based on evidence rather than tradition.
Evidence for novel agents is based on large phase III studies, with
proven survival and quality of life beneﬁts. Data for vintage sec-
ondary hormones are based on small short term phase II studies,
with proven beneﬁts on PSA progression only. Therefore, delay in
the initiation of the most effective agents may be detrimental.
Both the COU-302 and PREVAIL trials have demonstrated that
early initiation of novel agents are associated with improved sur-
vival. Although there is no strong evidence to support the use of
second-line traditional secondary hormone, there is no strong ev-
idence to exclude their use either.
The 2015 St Gallen Advanced Prostate Cancer Consensus rec-
ommends opting for abiraterone and enzalutamide if they are
available. Only when these agents are unavailable, should vintage
second-line hormonal manipulation be considered, as the use of
these traditional antiandrogens ﬁrst may increase the risk of
emergence of resistant tumour clones. Where possible, their use
should be limited to selected patients, and avoided in patients with
progressive disease.163. Summary
The opportunity to change the natural history of prostate cancer
is upon us. One of the most common molecular aberrations in the
development of castrate resistance is changes in androgen receptor
signalling, especially ampliﬁcation.21 Furthermore, changes in
message, enhancer and splice variants at the epigenetic and tran-
scription levels are emerging as additional mechanisms for
enhanced prostate cancer cell survival. With the arrival of more
powerful androgen synthesis and/or receptor pathway inhibitors,
delay in progression leading to improvements in overall survival
have been demonstrated in early clinical studies. Signiﬁcant ques-
tions remain regarding correlation between this new understand-
ing of molecular pathology and these new targeted strategies; not
only in terms of response but more importantly in terms of
mechanisms of de novo as well as acquired resistance. Investigators
can envisage studies investigating the potential for intermittent
compared to continuous therapy; dose modiﬁcations according to
molecular biomarker correlations and ﬁnally the potential for
sequential targeted therapy strategies according to the evolution of
molecular changes. Close collaboration between academic clini-
cians, pharma and regulatory authorities is needed tomaximise the
cost-effectiveness of this rapidly evolving ﬁeld.Conﬂict of interest
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